Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56‐positive acute leukemias
eJHaem · 2025-02 · 6 (1)
DOI: 10.1002/jha2.1052 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 16.12.2024. Verfasst von Hanan Hamdan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology University of Texas Southwestern Medical Center Dallas Texas USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background
Acute myeloid leukemia (AML) with RAM immunophenotype is a newly recognized high‐risk AML immunophenotypic subcategory characterized by blasts with bright expression of CD56 and weak to absent expression of CD45, HLA‐DR, and CD38, as first described by the Children's Oncology Group (COG). The relationship between AML‐RAM and other CD56‐positive acute leukemias is unclear. The goal of this study is to characterize the clinicopathological characteristics of AML with RAM phenotype and compare them with other CD56 co‐expressing acute leukemias.
Methods
From a multi‐institutional search, we identified a total of 160 CD56+ acute leukemia cases, including AML‐RAM ( n = 28), CD56+ acute undifferentiated leukemia (AUL) ( n = 11), CD56+ T‐lymphoblastic leukemia ( n = 39), and CD56+ AML ( n = 81). We compared the clinical and pathologic findings of these groups.
Results
AML‐RAM patients were significantly younger and presented with significantly higher platelet and white blood cell counts and bone marrow (BM) blast percentages when compared to AUL ( p > 0.05) and had higher median BM blast percentages than T‐ALL and CD56+ AML groups (both p < 0.05). Flow cytometry showed significantly brighter expression of CD56 on blasts as compared to other CD56+ AML cases, partial CD34 expression compared to AUL, and AML, weak‐to‐absent CD38 expression compared to all groups, and absent HLA‐DR and terminal deoxynucleotidyl transferase as compared to AUL and T‐ALL (all p < 0.05). The frequency of abnormal karyotypes was significantly higher among RAM when compared to all groups ( p < 0.05). Next‐generation sequencing profiles differed among the leukemia groups, with significant enrichment of CBFA2T3::GLIS2 fusions ( p < 0.05) and TP53 mutations ( p < 0.05) in RAM cases compared to other AML control groups, and U2AF1 ( p < 0.05), serine and arginine‐rich splicing factor 2 ( p < 0.05), and BCL6 co‐repressor ( p < 0.05) mutations compared to AUL. Clinical outcome analysis demonstrated significantly lower 3‐year overall survival of the RAM subgroup (36 months) compared to control groups ( p = 0.002).
Conclusion
We find that AML with RAM phenotype occurs primarily in younger ages, with distinct clinicopathological, immunophenotypic, and mutational presentations, and worse prognosis. This diagnosis should be considered in the clinical differential diagnosis of CD56‐positive acute leukemias.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology University of Texas Southwestern Medical Center Dallas Texas USA.
- Department of Pathology St. Jude Children's Research Hospital Memphis Tennessee USA.
- Department of Hematopathology, Division of Pathology/Lab Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA.
- Department of Pathology Boston Children's Hospital (BCH) Boston Massachusetts USA.
- Department of Pathology Seattle Children's Hospital Seattle Washington USA.
- Department of Pathology Yale School of Medicine New Haven Connecticut USA.
ORCID-Profile: Jacob Bledsoe, Alexa Siddon, Adam Bagg, Weina Chen, Olga K Weinberg
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
Zitieren
APA
Hamdan, H., Liu, Y. C., Wang, S. A., Bledsoe, J., Chisholm, K. M., Siddon, A., Ohgami, R., George, T. I., Kurzer, J., Hasserjian, R. P., Arber, D. A., Bagg, A., Foucar, K., Margolskee, E., Laczko, D., Chen, W., Fuda, F., Aggarwal, N., & Weinberg, O. K. (2025). Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56‐positive acute leukemias. eJHaem, 6(1). https://doi.org/10.1002/jha2.1052
Vancouver
Hamdan H, Liu YC, Wang SA, Bledsoe J, Chisholm KM, Siddon A, et al. Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56‐positive acute leukemias. eJHaem. 2025;6(1). doi:10.1002/jha2.1052
BibTeX
@article{Hamdan2025,
author = {Hamdan, Hanan and Liu, Yen-Chun and Wang, Sa A and Bledsoe, Jacob and Chisholm, Karen M and Siddon, Alexa and Ohgami, Robert and George, Tracy I and Kurzer, Jason and Hasserjian, Robert P and Arber, Daniel A and Bagg, Adam and Foucar, Kathryn and Margolskee, Elizabeth and Laczko, Dorottya and Chen, Weina and Fuda, Franklin and Aggarwal, Nidhi and Weinberg, Olga K},
title = {Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56‐positive acute leukemias},
journal = {eJHaem},
year = {2025},
volume = {6},
number = {1},
doi = {10.1002/jha2.1052}
}
EUVIMED